At the Epilepsy Foundation Central & South Texas, our mission is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

On January 10, 2020, the U.S. Food & Drug Administration (FDA) announced a recall on Lamotrigine Tablets USP 100 mg by Taro Pharmaceuticals. The recalled tablets may contain small amounts of Enalapril Maleate. Enalapril Maleate is a drug indicated for hypertension and congestive heart failure. Lamotrigine 100 mg Tablets are indicated for epilepsy and bipolar disorder. 

Epilepsy patients taking Lamotrigine regular release 100 mg manufactured by Taro Pharmaceuticals with lot #331771 should stop using this product immediately and return it to the pharmacy that dispensed it.  Please contact your pharmacist or doctor’s office if any new or unusual side effects occur. If you aren’t sure if your tablets are included in the recall, please check with your pharmacy.

Additionally, if you are experiencing any reactions, you are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:  

Complete and submit the report online.

Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the form, or submit by fax to 1-800-FDA-0178. Read the article from the U.S. Food & Drug Administration (FDA) here.

Tags:
,